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Summary. In 2 clinical studies in 40 conscious human volun- 
teers and 164 orthopedic patients histamine-release r - 
sponses were diagnosed, defined and classified. Polygeline 
(Haemaccel) in its now outdated formulation [40] was cho- 
sen as a clinical histamine releaser. The main interest was 
not concentrated on the extreme, the "classical" anaphy- 
lactic response, but on the average histamine-release re-
sponse found in clinical experiments with so many drugs 
in the last 10 years. 
In human volunteers 600 ng/kg histamine was i.v. in- 
jected. Indicants for a systemic anaphylactoid reaction with 
the highest incidence ratio were tachycardia, plasma hista- 
mine levels > t ng/ml, "metallic taste", flush, congestion 
of head, "wet eyes" and tears, hypertension and headache. 
Following polygeline none of these subjects developed a
life-threatening reaction, but 12 showed a systemic re- 
sponse, 11 a cutaneous reaction and 17 were non-re- 
sponders. Indieants for a systemic anaphylactoid reaction 
with the highest incidence ratio were plasma histamine lev- 
els > 1 ng/ml, tachycardia, wheals, sensation of heat, nar- 
rowness of  throat, hypertension, headache and wet eyes 
or tears. 
In a prolective, cohort study in the orthopedic patients 
3 subjects with life-threatening reactions, 27 with systemic 
response, 96 with cutaneous reaction and 38 non-re- 
sponders were included. Indicants with the highest inci- 
dence ratio were tachycardia, plasma histamine levels 
> 1 ng/ml, erythema nd wheals, cough, flush, stuffy nose 
and facial oedema. With this trial the indicants for diagnos- 
ing a systemic histamine release response in volunteers were 
validated in patients to a large extent. 
Thus the average histamine-release response was defined 
by clinical signs such as tachycardia and mild hypertension, 
scattered hives such as spots of erythema nd wheals, respi- 
ratory symptoms in the laryngeal and nasal region, such 
as cough, narrowness in the throat, stuff), nose and sneezing 
and by pathological plasma histamine levels (> 1 ng/ml), in 
addition histamine-release responses were differentiated as 
cutaneous responses, systemic responses and life-threaten- 
ing responses by clinical and operational criteria and by 
plasma histamine levels. Using clinical trials and medical 
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decision making procedures the incidence of systemic hista- 
mine-release r sponses in patients higher by two orders of 
magnitude than in other studies reported hitherto. 
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Definition und Klassifikation yon Histaminfreisetzung 
nach Gabe von Arzneimitteln in An~isthesie 
und Chirurgie: Studien am wachen Menschen 
Zusammenfassung:: In 2 klinischen Studien bei~ 40 wachen 
Freiwiltigen und 164 orthop/idischen Patienten wurde ver- 
sucht, Histaminfreisetzungsreaktionen zu diagnostizieren, 
zu definieren und zu klassifizieren. Haemaccel in einer heute 
klinisch nicht mehr verwendeten Zubereitung [40] wurde 
als klinischer Histaminfreisetzer v rwendet. Das Hauptinte- 
resse gait nicht der extremen, der klassischen anaphylak- 
tischen Reaktion, sondern einer durchschnittlichen Hist- 
aminfreisetzung, die in ktinischen Untersuchungen der letz- 
ten 10 Jahre mit so vielen Arzneimitteln gefunden wurde. 
Bei den Freiwitligen wurden 600 ng/kg Histamin intra- 
venrs verabreicht. Indikatoren ffir eine systemische anaphy- 
laktoide Reaktion mit der hrchsten Inzidenzrate waren Ta- 
chykardie, Plasmahistaminspiegel fiber 1 ng/ml, metal- 
lischer Geschmack, Flush, Kopfdruck, feuchte Augen oder 
Trfinen, Hypertension und Kopfschmerzen. Nach Haemac- 
cel-Infusion zeigte keiner der Probanden eine lebensbedroh- 
liche Reaktion, abet 12 eine systemische und 11 eine Haut- 
reakfion, w/ihrend bei 17 keine Symptome gefunden werden 
konnten. [ndikatoren mit der hrchsten Inzidenzrate waren 
wiederum Plasmahistaminspiegel fiber 1 ng/ml, Tachykar- 
die, Quaddeln, Hitzegeffihl, Enge im Hals, Hypertension, 
Kopfschmerzen und Tr/inen. 
In einer prolektiven Cohortstudie wurden aus 600 or- 
thop~idischen Patienten t64 ausgew~ihlt: 3 hatten eine le- 
bensbedrohliche R aktion, 27 eine systemische und 96 eine 
Hautreaktion, 38 Patienten zeigtcn keine Symptome. tndi- 
katoren mit der hrchsten Inzidenzrate waren wiederum Ta- 
chykardie, Plasmahistaminspiegel fiber 1 ng/ml, Erytheme 
und Quaddeln, Husten, Flush, verstopfte Nase und Ge- 
sichtsrdem. Damit wurden dutch die Patientenstudie die 
Indikatoren f/it eine systemische Histaminfreisetzungsreak- 
tion in Probanden zu einem grol3en Teil validiert. So 1/il3t 
sich eine durchschnittliche Histaminfreisetzungsreaktion als 
eine systemische anaphylaktoide R aktion charakterisieren, 
mit klinischen Symptomen wie Tachykardie und leichte Hy- 
pertension, verstreuten Effloreszenzen, respiratorischen 
Symptomen im Bereich des Kehlkopfs und der Nasen- 
schleimhaut und durch pathologische Plasmahistaminspie- 
gel (>1 ng/ml). Augerdem wurden die Histaminfreiset- 
zungsreaktionen in kutane, systemische und lebensbedroh- 
liche Reaktionen eingeteilt, wobei klinische und operafio- 
nale Kriterien sowie Plasmahistaminspiegel fiir die Klassifi- 
kation verwendet wurden. 
Sehliisselwiirter: Histaminfreisetzung- D iagnose-  Proban- 
den - Patienten - Medizinische Entscheidungsfindung. 
Introduction 
Before reliable and practicable [20] histamine assays in hu- 
man plasma became available for routine use [4, 26, 27] 
a histamine-release r sponse to drugs could not be esti- 
mated in clinical conditions with an acceptable accuracy 
[9, 10, 28, 29, 34, 36, 45, 51, 58, 62]. But even one decade 
after the discovery of H2-receptor antagonists [5] and the 
development of these highly sensitive and specific asays [4, 
26] histamine was still not generally recognized as an impor- 
tant mediator of  any pathological and clinical phenomenon 
[63]. It was something of a paradigm [22a] not to assign 
any distinct function to this biogenie amine - neither qualita- 
tively nor quantitatively [13]. 
In the labyrinth of  intricate views on histamine this dis- 
appointing situation could be amended by only step by 
step. A very early, necessary and urgent one was to estab- 
lish the diagnosis of the histamine-release response to an 
individual drug in clinical conditions, especially in anaesthe- 
sia and surgery where so many histamine-releasing drugs 
are routinely administered intravenously [39]. The main in- 
terest in this study therefore was not concentrated on the 
extreme, the "classical anaphylactic" response, but on the 
average response which was found in clinical experiments 
with so many drugs during the last 10 years. Thus two 
aims were devised in this investigation: 
(l) In conscious human volunteers clinical symptoms 
and plasma histamine levels were assessed after intravenous 
injection of  histamine. A dose was chosen which increased 
the plasma histamine levels to such an extent as the average 
histamine-release response to drugs used in anaesthesia [28, 
34]. In addition, the same subjects received one of the "clin- 
ical" histamine releasers, polygeline (Haemaccel) [29, 34, 
39, 40) a short time after exogenous histamine. From all 
the findings a questionnaire with many items was developed 
to diagnose an average histamine-release response. 
(2) Using these items in conscious orthopedic patients 
the clinical symptoms, biological reactions and plasma his- 
tamine levels were assessed which were elicited by Haemac- 
eel, the same histamine liberator as used in the volunteers. 
By this study the set of  indicants for diagnosing a histamine- 
release response was validated. Parts of this very extended 
study have already been published in other journals [1, 
35-40]. The subject of this presentation, however, was not 
considered in the previous communications. 
Materials and Methods 
1. Theoretical nd Ethical Issues [41] 
The aim of the study could not be achieved by a single technique 
(e. g. a single biochemical test). Among several approaches a de- 
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(1) Was the drug really given or taken? 
(2) Symptoms similar to those elicited 
~ by free histamine? 
(3) ~ ~ (3) Changes in histamine content of 
-/ \+ -/ ~4 tissues and body fluids? 
[~](4)~ [~] ~ (4) Exogenous histamine 
/ ~ / /  ~ as contamination ?
(5) ~ .C~ (5) No other drugs given at the 
- /  "~ #f ~ same time? 
/ "/ \+ / -/ \÷ mine releasers? 
~7) ~ ~ el ~ ~ ~ (7) oo~s the ~e~ ~-  
~ ~/ ~] ~ ~// ~ lease h|stamme'~ 
subclinical clinical 
OK! The patient has a histamine-release response to the drug 
Fig. 1, Decision tree for diagnosis of hkstamine-retease response 
to an individual drug in an individual patient. The open circles 
represent est nodes, the plus or minus branches the preceding 
facts or findings which are necessary toestablish finally the diagno- 
sis. The tree structure was performed according to Lusted [43]. 
The small squares denote steps of the decision-making process 
(dead ends), not choice nodes as in a modified system of displaying 
the decision problem [68]. The arrows indicate the final outcome 
of a clinical or subclinical histamine-release re ponse 
cision-making process was chosen for a first approximation which 
was illustrated by a decision tree (Fig. 1). The designs of the two 
prospective studies in volunteers and patients payed regard to all 
the questions in this structure. 
The decision tree showed 4 paths and 3 outcomes comprising 
clinical, subclinical nd indeterminable histamine-release r sponse 
to an individual drug. Subclinical reactions were included since 
they were of considerable interest for a second rug exposure and 
other complications after surgery [66]. For the aims of the two 
clinical trials, however, the second path from the right was the most 
important one including symptoms, changes in plasma histamine 
content, no contamination with exogenous histamine, no other his- 
tamine releasers given a d a highly inert solvent system. Since 
the final outcome (diagnosis of a clinical response) hould depend 
mainly on findings obtained by the questions 2 and 3, the studies 
had to be conceived in such a way that the other information 
was obtained with the highest possible precision andaccuracy. 
To achieve this aim the following conditions numbered inagree- 
ment with the decision tree were chosen: 
(1) Exogenous histamine and the histamine releaser polygeline 
(Haemaccel) were given to the human subjects by a single investiga- 
tor (author), to volunteers by B.G. and to patients by B.Sch. 
(2) Clinical signs were recorded by a single observer, too, in volun- 
teers by W.L. and in patients by B,Sch. Thus observer variation 
within the trials could be avoided. Between the trials it was reduced 
by discussions in detail of all defintions of the various indicants 
by the observer in volunteers with the observer in patients [16, 
43]. 
In volunteers a dose f 600 ng/kg i.v. exogenous histamine was 
expected to produce plasma histamine levels similar to those of 
an average histamine-release r sponse (pilot s udy in volunteers 
and in dogs [30]). An injection was chosen because of pharmacokin- 
etics more similar to histamine release than histamine infusion. 
The intravenous route corresponded to histamine release from the 
skin which is common for many histamine liberators [47] including 
Haemaccel [30], To avoid tachyphylaxis and prolonged elevation 
of plasma histamine content exogenous histamine was applied be- 
.fore potygeline. 
Polygeline was tested in a dose of 500 ml/3 rain in normovo- 
laemic haemodiluation [34] since this design repeatedly has pro- 
duced average histamine-release responses [28, 33-35, 54]. Hae- 
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maccel as a plasma substitute was pure and chemically defined 
and could be administered in clinical conditions where no other 
drug, solvent or treatment interferes [34]. Histamine release by 
this drug was predominant [13, 35] i.e. no other mediator seemed 
to be of any importance in the reaction to polygeline [35]. Its 
incidence was sufficiently high in clinical situations and its mecha- 
nisms were reasonably uniform [39, 40, 56]. 
In patients the infusion of 500 ml/10 min Haemaccel before op- 
eration was indicated for therapeutic reasons [62a]. This decision 
was made by clinicians responsible for the patients and not by 
those involved in the trial. The administration of polygeline in 
conscious patients, however, was utilized for this study since anaes- 
thesia was considered to modify, but not in general to reduce the 
extent of the clinical reaction [46]. 
(3) All plasma histamine assays were performed by a single techni- 
cian who was not aware of the clinical reactions and received the 
plasma samples in a randomized sequence. The assays run under 
quality control using a mixed control plasma prepared from the 
patients of the trial in Heidelberg and control charts according 
to Levey and Jennings [24]. 
(4) Polygeline was tested in several batches to obtain a random 
distribution of histamine-release responses over the manufacturing 
process. In none of the 4 batches administered to volunteers and 
patients could any histamine contamination be detected. In addi- 
tion, the fluorescent material in polygeline [31] was shown not 
to interfere with the histamine assay using several tests of identifica- 
tion [32]. 
(5) Interference with other drugs was prevented by controlling meti- 
culously the time before and after histamine and polygeline admin- 
istration. Histamine release was considered as a sudden event with 
an explosive velocity of increment for plasma histamine levels [36] 
followed by a rather quick elimination (plasma t 1/z for i. v. injected 
histamine about 2 min, for histamine release about 5--10 min [30, 
361. 
Thus in volunteers all subjects were systematically asked for 
any drug intake at the day of experiment by a single observer 
(W.L.) and 2 of them were excluded since this was the case. Follow- 
ing i.v. histamine injection 20 rain elapsed before polygeline was 
infused. Basal plasma histamine levels were again attained at this 
time (Fig. 5). 
In patients only elective surgery was accepted. The night before 
operation they received standard treatment (only nitrazepam and 
heptabarbitone). In the morning the premedication tbr anaesthe- 
sia started with the infusion of polygeline. Inovar (in Germany 
known as Thalamonal) and atropine, the other two components 
of the premedication were administered not prior than 30 min after 
the start of infusion which lasted not longer than 10 rain. Patients 
who needed additional drugs for treatment of concomitant diseases 
such as/~-adrenoceptor blocking drugs or digitalis received these 
compounds very early in the morning and not later than 2 h before 
starting the infusion of polygeline. 
(6) In clinical conditions none of these drugs was hitherto suspected 
to be a histamine releaser [36, 39]. 
(7) Histamine was dissolved in saline and polygeline in a slightly 
modified Ringer solution which was hown not to release histamine 
[34]. 
Ethical Just~cation. In volunteers informed consent was obtained 
in written form following an extensive discussion about the impor- 
tance and necessity of the study, the experimental design and the 
risks of a histamine injection, blood donation and infusion of a 
histamine releaser. It was explained that at the time of the study 
(March 1976) no colloidal plasma substitute commercially avail- 
able was entirely without risk of inducing an anaphylactoid re- 
sponse [34, 52, 54]. At the time of the study polygeline it its now 
outdated formulation ("classical polygeline" [40]) had been given 
to patients all over the world for more than 10 years. Utmost 
safety was provided for each volunteer during the clinical experi- 
ment by at least 2 anaesthesists being present in the room all the 
Table 1. Attributes of the subjects in the volunteer study 
Attributes ~ (interquartile 
range, range) 
Age [years] 
Weight [kg] 
Sex (male/female) 
Profession (S-M, S-NM, HS, NHS) 
Allergy in past (yes/no) 
Allergy at present (yes/no) 
Previous infusion of colloidal 
plasma substitutes (yes/no) 
26 (23-29, 21-37) 
70 (62-75, 50-94) 
Ratio of numbers 
32/8 
12ii3/10/s 
9/31 
10/30 
10/30 
S-M student of medicine, S-NM student not studying medicine, 
HS hospital staff, NtIS other professions, but not hospital staff 
(e. g. civil servant, engineer, photographer). Allergy in past = more 
than 9 months ago, allergy at present=from 9 months in the past 
until now. Previous infusion of plasma substitutes included 9 sub- 
jects who were included in previous trials (the last 2 years before) 
time. All emergency equipment was in the room and ready for 
use. In addition, all volunteers were asked to inform the investiga- 
tors the day after the experiment about their state of health. There 
was no complaint by any of them. 
In orthopaedic patients no safer alternative treatment was avail- 
able. The patients were informed about additional taking of blood 
samples for plasma histamine assays. Utmost safety was provided 
for each patient in the same way as for each subject in the volunteer 
study. 
2. Time Schedule, Volunteers and Patients, Materials 
The volunteer study was conducted in 40 subjects (Table 1) in Mun- 
ich at March 8-13, 1976. For this trial histamine dihydrochloride 
puriss. (Fluka, Buchs) was dissolved in sterile saline (2 mg/100 ml, 
University's pharmacy). Only 2.5-5 ml were injected to achieve 
a reliable bolus injection. - Polygeline (Haemaccel, Behringwerke 
Marburg) was infused in 4 batches (Op 3000 and 3812, V-235 
and V-244) which were characterized in previous communications 
[31, 32, 34, 40] regarding their chemical and pharmacological prop- 
erties. The 40 volunteers were assigned to 4 treatment groups (1 
batch for one group) by a balanced random allocation with random 
digits. This part of the study was a double-blind trial [40]. The 
patient study was conducted in 164 subjects in Heidelberg from 
March 14, 1977 till January 12, 1978. They were selected from 600 
patients in a controlled clinical trial [36, 38-40] who after prolective 
stratification comprised both sexes divided into 5 classes of age 
(20->60 years, 30 patients in each cell). The selection became 
necessary since the plasma histamine assays were too time-consum- 
ing and expensive to be carried out in all patients. The procedure 
for selection is shown in Table 2: (1) In all participants of the 
trial with clinical symptoms of an anaphylactoid reaction [35] 
blood was taken for plasma histamine assays. From a previous 
trial [54] 30 incidents were expected and fortunately also found. 
(2) To avoid seasonal variations or bias introduced by new drugs 
or treatment during the study the control group with "no adverse 
response" was formed by selecting always the next two patients 
following the last one with an anaphylactoid reaction. It was ex- 
pected that some of these patients would develop an allergoid reac- 
tion (response restricted o the skin) [35]. By that the sample of 
true non-responders would be reduced to approximately the same 
size as that of the sample with anaphytactoid reactions. In this 
aspect the selection was rather successful (Table 2). (3) Then a 
second control group was formed with patients "showing only 
allergoid reactions" to discriminate between anaphylactoid (sys- 
temic) and allergoid (cutaneous) reactions to polygeline. For this 
clinically very important classification a compromise was chosen 
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Table 2. Patients in the clinical trial on histamine release by polyge- 
line and proportions of those involved in the plasma histamine 
assay 
Reaction Expected a Found 
to polygeline 
Patients Pro- Patients Pro- 
in trial portion in trial portion 
for for 
In] [%]b hista- [nl [%] hista- 
mine mine 
Anaphylactoid 30 5 30 30 5 30 
No response 420 70 50 413 69 38 
Allergoid 150 25 100 157 26 96 
Total 600 100 180 600 100 164 
" Frequencies and rate according to Schtning and Koch [54] 
b Percentage of patients in the trial. 4 patients in the third group 
were lost by failures of centrifugation, 4 were excluded because 
they could not unequivocally be classified as "no responders" or 
"patients with allergoid reaction". Sex distribution (male/female) 
in the three groups: Anaphylactoid 24/6, no response 16/22, aller- 
gold 56/40 patients. Age distribution in the three groups (20-29, 
30-39, 4049, 50-59, >60 years): Anaphylactoid 6/10/5/6/3 - no 
response 7/8/7/8/8 - allergoid 18/20/29/14/15. The differences were 
not considered as influencing the incidence ratio of pathological 
plasma histamine levels and clinical symptoms 
between maximum information and feasibility selecting two-thirds 
of patients with allergoid reactions for plasma histamine assays 
by random allocation with random digits. Selection and randomi- 
zation procedure could only be realized because plasma was pre- 
pared from all 600 patients in the study before polygeline infusion. 
Plasma of patients which was not used for histamine assays was 
pooled for quality control samples. 
Polygeline was infused in 4 batches (Op 3939 and 3946, V-244 
and V-265). The 600 patients were assigned to 4 treatment groups 
(1 batch for one group). This part of the study again was a double- 
blind trial. However, no differences were found in the incidence 
of reactions between the 4 batches [38]. 
Reagents for plasma histamine assays were the same as de- 
scribed by Lorenz et al. [27, 32]. 
3. Experimental Design 
(1) In volunteers the investigation started with a half-structural 
interview including questions on case history to identify special 
risks of anaphylactoid reactions to plasma substitutes [34], ques- 
tions on previous exposure to intravenous agents [28, 65, 66] and 
on clinical signs appearing even before injection of histamine. The 
clinical symptoms were chosen from previous reports [23, 59, 69] 
and earlier studies [28, 33, 34]. The volunteer was asked to give 
his informed consent. 
Thereafter in the laying subject leads for the ECG were at- 
tached to the extremities and a sphygmomanometer was applied 
to the right upper arm. Two Braunulae were inserted in this arm, 
one in the cubital fossa for injection of histamine and one more 
peripheral for the venous blood collection. A first 20 ml sample 
was taken to produce plasma for a pool which was used for quality 
control samples. Five minutes later a second sample was taken 
to obtain the pre-injection plasma histamine level. Then histamine 
was administered and blood was taken at 1, 2, 3, 5 and 10 min 
after its application. During this time the volunteer was asked 
about and carefully looked for any clinical symptoms. First of 
all, spontaneous reactions were recorded, then all questions asked 
before the injection were repeated 3 and 10 min after histamine 
injection. 
Fifteen minutes after histamine injection blood donation 
(360 ml) was started from the left arm and 1 min later polygeline 
was infused (500 ml, in about 3 min). Blood samples for plasma 
histamine were taken 1, 5, 10, 15 and 20 min after the end of 
infusion and during this time the clinical symptoms were recorded 
as described before. Thoughout he experiment the heart rate was 
continuously monitored (lead II in ECG) and the blood pressure 
was measured every min. 
From the questions, observations and responses of the volun- 
teers a questionnaire was developed with indicants for diagnosing 
a histamine-release response (Appendix 1). 
(2) Also inpatients the investigation started with an interview using 
the questionnaire in a protocol ready for electron data processing 
[57]. Then pulse rate (by hand) and blood pressure (by sphygmo- 
manometer) were measured and a large arm vein was cannulated 
by a Braunula No. 1. For plasma histamine assay blood samptes 
were taken 5 rain later before polygeline (500 ml) was infused in 
10-15 min, at the end of the infusion and again 5 min later to 
get parts of a clearance curve as in the volunteers [39]. At the 
end of the infusion, 5, 15 and 30 rain later pulse and blood pressure 
were measured and any clinical symptoms - especially any skin 
reactions - were systematically ooked for even by turning the 
patient round and inspecting all parts of the body. The protocol 
was tested for its completeness and any observations to be added 
were specified. For plasma preparation [27] blood was centrifuged 
in a Minifuge (Christ, Osterode) in the operation theatre [27]. 
4. Me~o~ 
Clinical symptoms and reactions were assessed using the question- 
naire described in this communication. - Plasma was prepared 
and plasma histamine concentration was determined according to 
Lorenz et at. [27] using a sensitive and specific fluorometric-ftuor- 
oenzymatic assay. - In all cases with anaphylactoid reactions hista- 
mine was identified by fluorescence spectra, :heating test and spec- 
tra after the heating test as described by Lorenz et al. [32] and 
Parkin et al. [48]. - All assays were performed under quality con- 
trol using two plasma pools obtained from volunteers and patients 
to which authentic histamine was added to give "plasma" hista- 
mine levels similar to those of an average histamine-release re- 
sponse (about 3 ng/ml). 
5. Statistics and Definitions 
For descriptive statistics median, interquartile range, range and 
incidence ratio were used, for inferential statistics 95% confidence 
intervals and decision-making matrix [15, 43, 68]. The correlation 
between plasma histamine levels and increase in heart rate (tachy- 
cardia) was analysed by the method of least squares using a Hew- 
lett-Packard computer HP 9815 A. 
A crucial question in this study was the definition of the "dis- 
ease". In the first part of the volunteer study the disease was an 
anaphylactoid-like r action to the i.v. injection of histamine, in 
the second part of this study and in the clinical trial the disease 
was a true anaphylactoid or allergoid (cutaneous anaphylactoid) 
reaction to polygetine. The similarity of the two "diseases" in 
terms of diagnosis was one of the most important questions of 
this article. 
Thus anaphylactoid and allergoid reactions have to be defined 
[39]: (1) An anaphylactoid reaction is a clinical reaction with gener- 
alized urticaria (more than 5 wheals in different regions of the 
body), discomfort (nasal catarrh, narrowness of the throat, ble- 
pharoedema, nausea or vomiting, diarrhoea), bronchospasm, ta- 
chycardia, hypotension, circulatory and cardiac insufficiency and 
arrest. At least generalized urticaria plus discomfort (except dermal 
pruritus) were necessary to classify an adverse reaction to drugs 
as anaphylactoid. Generalized urticaria plus tachycardia, but also 
bronchospasm, cardiac arrhythmia, hypotension or cardiac arrest 
with or without urticaria are other combinations of clinical signs 
being classified as anaphylactoid. (2) An allergoid (cutaneous ana- 
phylactoid) reaction is again a clinical reaction classified by eryth- 
ema, urticaria and dermal pruritus only. Lateron in this article 
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Fig. 2. Histamine limination curves following i.v. injection of ex- 
ogenous histamine (600 ng/kg). Single values obtained from the 
volunteers, n refers to the number of subjects howing the attribute, 
No refers to the number of a single person in the sequence of 
the experiments. Since in one of the subjects only the first sample 
after histamine injection was lost, but all other values corresponded 
to those of the type-(a)-elimination curve this subject was not ex- 
cluded in the figure. For further conditions ee Materials and 
Methods 
anaphylactoid reaction will be replaced by s stemic histamine-re- 
lease response. In terms of taxonomy of diseases the systemic hista- 
n-tine-release r sponse isa special case of an anaphylactoid reaction 
which in its turn is a special case of a pseudo-allergic reaction 
[12, 22, 391. 
Another crucial question in this study was the defintion of 
a pathological p asma histamine l vel as indicant for an anaphylac- 
toid reaction. (1) It is defined as top level obtained by measuring 
several values in a Bateman function. (2) It is defined as positive 
or pathological if it is higher than 1 ng/ml which is the upper 
2 SD limit of the "normal range". Considering well the criticism 
of this concept [18] it is emphasized that since 1975 the normal 
range of plasma histamine values has been always 0--1 ng/ml in 
studies with 120 [33] and 40 [37] volunteers and in 50 [39] and 
299 [55] patients of both sexes and 5 classes of age using our 
fluorometric-fluoroenzymatic assay [27, 39]. 
Resu l ts  
1. Plasma Histamine Levels andClinical Signs 
in Volunteers Following Administration 
of Exogenous Histamine 
Histamine elimination curves showed 3 typical patterns 
(Fig. 2): A "normal"  type in 80% of the subjects howed 
first-order kinetics, but in 20% a "de layed"  type or a "red-  
istr ibut ion" type was found, probably due to difficulties 
with the bolus injection. Such "fa i lures"occur also in clini- 
cal routine [39]. For  assessing the incidence ratio, however, 
the pathological plasma histamine values the one subject 
in whom the first plasma was lost and the three with " red-  
istr ibut ion" type curves were excluded (Fig. 3, Table 3). 
F rom the data in the other 36 volunteers, however, it 
was evident, that the imitation of  an anaphylactoid reaction 
by injection of  histamine was reasonably successful (Fig. 3). 
Eighty percent of the plasma histamine levels exceeded 1 ng/ 
ml and the average concentration was about 1 .52  ng/ml, 
similar to that found in histamine-release responses to an- 
aesthetics and plasma substitutes [10, 34]. In 2 subjects plas- 
ma histamine levels of  about 4 ng/ml were measured, ac- 
companied by considerable tachycardia. In 8 subjects in- 
creases of plasma histamine levels could be determined, but 
were rather small and did not exceed the normal range. 
The variation in plasma histamine levels following the same 
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Fig. 3. Plasma histamine levels before 
and after injection of histamine in 
volunteers in whom an anaphylactoid 
reaction was imitated by i.v. 
administration f only 600 ng/kg 
histamine. Single values obtained from 
each of the volunteers before and after 
histamine injection. The vertical dotted 
line indicates the cut-off point for an 
anaphylactoid reaction as described in 
Methods 
Tab le  3. Incidence ratio for pathological plasma histamine levels 
and clinical signs in "anaphylactoid" reactions imitated in volun- 
teers by i.v. injection of histamine 
Symptom Incidence 
na/n 2 % 95% 
confi -
dence 
interval 
Plasma histamine l vel > 1 ng/ml 28/36 78 60-90 
Skin: Flush 25/36 69 5t-84 
Erythema 4/36 1 t 3-27 
Sensation of heat 20/36 56 38-73 
Wheals 0/36 0 0-10 
Respiratory Narrowness of chest 11/36 31 16-49 
tract: Coughing 0/36 0 0-10 
Stoffy nose 0/36 0 0-10 
Circulation: Tachycardia 35/36 97 85-100 
Hypotension 6/36 17 6-33 
Hypertension 21/36 58 40-75 
Pulsation at temples 14/36 39 23-57 
Abdomen: Nausea 2/36 3 0-19 
Metallic taste 27/36 75 57-88 
Salivation 4/36 I 1 3-27 
CNS and Headache 21/36 58 40-75 
ANS: Outbreak of sweat 5/36 14 4-30 
"Wet eyes" 23/36 64 46-80 
Congestion of head 24/36 67 49-82 
Each symptom was recorded only once in a single volunteer, n 1 = 
number of subjects howing the symptom provided histamine was 
given, nz =number of subjects having the "anaphylactoid" reac- 
tion. All volunteers responded and fulfilled the conditions of the 
definition (see Materials and Methods). No treatment, however, 
was necessary in any of them (cf, Tables 4 and 5) 
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dose of  histamine was about 10-fold - a finding with some 
clinical relevance. The increases in plasma histamine con- 
centration following histamine injection were not normally 
distributed (cf. [30]) and were not correlated to the basal 
plasma histamine levels. All  these findings indicated a more 
complex situation for histamine l imination than the rather 
simple clearance curves (Fig. 3) had suggested. At  least ex- 
cretion by the kindey and gastro-intestinal tract, up-take 
into several tissues and a rapid metabolism were identified 
hitherto as components in elimination [39]. 
The incidence ratio of  pathological plasma histamine 
levels and clinical signs of  an "anaphy lacto id"  reaction 
varied considerably from indicant o indicant (Table 3). Al- 
though histamine was actually given to all volunteers and 
all of  them showed clinical signs of  a systemic response 
plasma histamine levels exceeding 1 ng/ml were found only 
in 80% of them. The clinical sign with the highest incidence 
was tachycardia, followed by sensation of  an unusual (" me- 
tall ic") taste, flush, congestion of  head, "wet  eyes", head- 
ache and hypertension(!). Classical symptoms of  anaphy- 
lactoid reactions such as wheals, respiratory symtoms and 
hypotension could not be observed. Although this is quite 
understandable (wheals occur only at high local histamine 
concentrations, respiratory and hypotensive responses 
appear at usually higher histamine concentrations), this 
finding is of  general clinical importance. An average hista- 
mine-release r sponse may not be diagnosed in clinical condi- 
tions because the place of histamine release may not be the 
skin, but the gut (cremophor El [39]) and because local 
histamine release in a vital organ such as the heart may not 
lead to cutaneous and respiratory symptoms, but only to mis- 
interpreted "unspecific" heart symptoms [25, 26a] 
A logical consequence of these conclusions was the ques- 
tion of which symptoms appeared at which plasma hista- 
mine concentrations. In the volunteer study there was no 
clear trend to establish such a relationship (Fig. 4). Howev- 
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a bolus injection 
er, several symptoms were rare and occurred at higher plas- 
ma histamine levels, such as sensations of "narrowness in 
the chest" and nausea. 
2. Plasma Histamine Levels and Clinical Signs 
in Volunteers Following I fusion of Polygeline 
Of 40 volunteers receiving all the full dose of  polygeline 
12 responded with an anaphylacoid reaction. They showed 
plasma histamine values of 0.3 (0-1.0) ng/ml (i and range) 
before and 1.9 (0.7-4.2)ng/ml after polygeline infusion. 
One subject fulfilled the criteria of  an anaphylactoid reac- 
tion, but his plasma histamine levels increased only from 
0 to 0.7 ng/ml and remained within the normal range. Since 
otherwise the data on plasma histamine were very similar 
to those obtained whith histamine injection a more ex- 
tended presentation i this chapter is omitted. 
To illustrate, however, the relations between plasma his- 
tamine levels, heart rate and blood pressure the 3 most 
impressive reactions in volunteers were shown in Fig. 5. 
In subject No 6 instead of tachycardia bradycardia was ob- 
served which was the only case in the series and hitherto 
had been found only in very rare cases of  histamine release. 
Table 4. Incidence ratio for pathological plasma histamine levels 
and clinical signs in anaphylactoid reactions in volunteers following 
infusion of polygeline 
Symptom Incidence 
nl/n2 % 95 ° 
confi- 
dence 
interval 
Plasma histamine level > 1 ng/ml 11/12 92 61-100 
Skin: Flush 4/12 33 9-66 
Erythema 3/12 25 5---58 
Sensation of heat 6/12 50 21-79 
Wheals 7/12 58 27-85 
Respi- Sneezing 3/12 25 5-58 
ratory Stoffy nose 1/12 8 0-39 
tract: Narrowness of the throat 6/12 50 21-79 
Coughing 3/12 25 5-58 
Respiratory distress 2/12 17 2-49 
Bronchospasm 1/12 8 0-39 
Circuta- Tachycardia 10/12 83 51-98 
tion: Hypertension 6/12 50 21-79 
Hypotension 0/12 0 0-27 
Abdo- Nausea 1/12 8 0-39 
men: Metallic taste 4/12 33 9-66 
Salivation 0/12 0 0-27 
CNS and Headache 5/12 42 15-73 
ANS: Outbreak of sweat t/12 8 0-39 
"Wet eyes", tears 5/12 42 15-73 
Agitation 2/12 17 2-49 
Congestion of head 0/12 0 0--27 
Treat- Hi-receptor antagonists 2/12 17 2-49 
merit: 6-Methylprednisolone 1/I 2 8 0-39 
Epinephrine 0/12 0 0-27 
Each symptom was recorded only once in a single volunteer, n 1 = 
number of subjects howing the symptom, n2 = number of subjects 
showing the anaphylactoid response 
The more long-lasting elevation of  plasma histamine levels 
in histamine-release responses than after histamine injection 
was remarkable, but could easily be explained in terms of 
pharmacokinetics by a longer invasion time. Finally, in 
none of the 3 volunteers hypotensive reactions occurred, 
but only slight hypertensive r sponses. 
The incidence ratio of  pathological plasma histamine 
levels and clinical signs of  an anaphylactoid reaction varied 
again from indicant to indicant (Table 4). Tachycardia was 
again the most frequent clinical symptom of an anaphylac- 
toid reaction. Hypertension, but not hypotension was ob- 
served at these plasma histamine levels. Once recognized 
as a typical histamine ffect (Table 3) the "metall ic" taste 
was also reported by the volunteers, headache, wet eyes 
or tears were also observed in about half of  the subjects. 
Treatment was necessary in two of the volunteers (No. 21 
and 33 in Fig. 5), an indicant which was rather complex 
and contained all the judgements of the two anaesthesiolo- 
gists in the team. However, no emergency treatment was 
necessary in any of  the volunteers. 
Several remarkable differences, however, were observed 
between histamine injection and histamine release by poty- 
geline despite the finding that the average plasma histamine 
Table 5. Incidence ratio for pathological plasma histamine levels 
and clinical signs in allergoid (cutaneous anaphylactoid) reactions 
of conscious volunteers and orthopedic patients following infusion 
of polygeline 
Symptom or indicant Incidence 
14(1 
nl/n 2 % 95% 
confi- 
dence 
interval 
a) volunteers 
P lasma histamine l vel > 1 ng/ml 0/11 0 0-29 14o- 
Skin: Flush 1/11 9 0-42 - 
Erythema 2/I 1 18 2-52 
Wheals and papules 10/11 9t 58-100 loo- 
Pruritus 5/11 45 16-77 
Respir. Sneezing 2/11 18 2-52 60_ 
tact: 
Abdo- 
men 
Metallic taste 2/11 18 2-52 
Swelling of parotid gland 1/11 9 0-42 
b) patients 
Plasma histamine l vel > 1 ng/ml 2/96 2 0- 7 
Skin: Flush 2/96 2 0- 7 
Erythema 10/96 t0 5-18 
Wheals and papules 90/96 94 89-98 
Pruritus 11/96 It 5-19 
Respir. Sneezing 0/96 0 4- 4 
tract: 
Abdo- Metallic taste 0/96 0 0- 4 
men: Sweeling of parotid gland 1/96 t 0- 5 
Each symptom was recorded only once in a single patient 
n 1 = number of patients with the particular indicant 
n2 = number of patients with allergoid reaction 
No tachycardia, no change in blood pressure was observed in any 
of the subjects following polygeline infusion 
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levels were quite similar in these two conditions. Flush and 
erythema were rather rare. Hives (wheals) were more fre- 
quent, but had to be searched for by very careful inspection 
of the whole body. Sneezing, narrowness of  the throat and 
cough were the most common respiratory symptoms, but 
could not be imitated by histamine injection (Table 3). 
In the volunteer study 11 subjects howed an allergoid 
reaction and 17 individuals were non-responders. Patholog- 
ical plasma histamine levels exceeding I ng/ml were ob- 
served in none of them (Table 5). Wheals and papules were 
the only indicants with an incidence ratio of more than 
50% in volunteers with allergoid reactions. 
3. Plasma Histamine Levels and Clinical Signs 
in Orthopedic Patients Following hfusion 
of PolygeIine 
An anaphylactoid reaction was observed in 30 patients cor- 
responding to 5% in the whole trial of 600 subjects. 3 of 
them were life-threatening (Fig. 6) corresponding to 0.5%. 
Reactions of  such a severity had never been elicited in vo- 
lunteers [34-36]. In 26 of the patients plasma histamine 
levels of more than I ng/ml were determined (Fig. 7), 4 of 
them were test-negative. The average plasma histamine level 
was 2.4 ng/ml which compares well with the 1.9 ng/ml in 
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Fig. 6. Life-threatening anaphylactoid reactions to potygetine in 
the clinical trial in orthopedic patients. Single values from each 
of the patients. In the first patient (P) the second blood sample 
was taken 2 min after the end of infusion and the third one 13 rain 
later. This exception from the protocol was caused by treatment 
of the patient. The attributes of the 3 patients were not especially 
different from those of the others in trial: Patient P.I. (65 years, 
male, 90 kg, Bohemian farmer, no history of allergy, received 
500 ml polygeline in 10 min (V265) without previous exposure to 
the drug). Patient K.Ph. (43, male, 80, South German industrial 
worker, allergy against penicillin) received 500 ml (V265) in 8 min 
without previous exposure to the drug. Patient F.W. (50, male, 
72, South German civil servant, no allergy) received 450 ml (V244) 
in 10 min without previous exposure to polygeline 
the volunteer study. The variation of  the values (0.(~20 ng/ 
ml), however, was greater than in volunteers after injection 
of histamine or infusion of polygeline. The pathological 
plasma histamine levels were not normally distributed and 
were not correlated to the basal plasma histamine levels 
(Fig. 7). Thus by measuring basal plasma histamine concen- 
trations before infusion responders and non-responders to po- 
lygeline could not be predicted. 
The incidence ratio of pathological plasma histamine 
levels and clinical signs of an anaphylactoid reaction varied 
from indicant to indicant as it was found in volunteers 
(Table 6). Tachycardia was again the most frequent symp- 
tom, erythema, wheals and cough had a high, flush only 
a medium and hypotension, nausea and outbreak of sweat 
a low incidence. It should be emphasized that hypotension 
as a clm;~icat histamine reaction is of very minor importance 
in diagnosing an average histamine-release response. 
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Table 6. Incidence ratio for pathological plasma histamine levels 
and clinical signs in anaphylactoid reactions of conscious ortho- 
pedic patients 
Symptom or indicant Incidence 
nl/n z % 95% 
coufl- 
dence 
interval 
Plasma histamine level > 1 ng/ml 26/30 87 70-96 
Skin: Flush 13/30 43 24-64 
Erythema 21/30 70 52-84 
Wheals 18/30 60 40-77 
Facial oedema 9/30 30 16-48 
Respiratory Sneezing 7/30 23 10-41 
tract : Stoffy nose 9/30 30 t 6-48 
Narrowness of throat 3/30 10 2-25 
Coughing 15/30 50 32-68 
Respiratory distress 5/30 17 6-33 
Bronchospasm 1/30 3 0-•7 
Circulation: Tachycardia 28/30 93 79-99 
Hypotension 3/30 10 2-25 
Abdomen: Nausea 7/30 23 10-41 
Vomiting 2/30 7 1-21 
Abdominal pain 1/30 3 0-17 
CNS and Headache 1/30 3 0-17 
vegetative Outbreak of sweat 1/30 3 0-17 
nervous Tears 1/30 3 0-17 
system: Agitation 3/30 10 2-25 
Treamaent: HI-receptor antagonists 23/30 77 59-90 
6-Methylprednisolone 6/30 20 9-37 
Stop of infusion 8/30 27 13-44 
Infusion 3/30 10 2-25 
Oxygen 1/30 3 0-I 7 
Epinephrine 1/30 3 0-17 
Each symptom was recorded only once in a single patient, l = 
number of subjects showing the symptom, n2 = number of subjects 
showing the anaphylactoid reaction 
Agreement in the incidence ratio of indicants between 
the 3 investigated conditions was very satisfactory for some 
of the symptoms, such as pathological plasma histamine 
level, tachycardia, flush, hypotension, ausea, and outbreak 
of sweat (Table 3, 4 and 6). More interesting however, were 
the many disagreements. We should not underestimate he 
series with histamine injection as a rather artificial condi- 
tion since histamine release may not always occur in the 
skin, but also selectively in the liver, the gut, the lungs 
or in other tissues with large histamine stores, and histamine 
may enter the circulation just in the way of a protracted 
histamine injection. The different incidences of symptoms 
between histamine injection (Table 3) and histamine-release 
(Tables 4 and 6) include those of wheals, facial oedema 
and rather all respiratory symptoms. All these symptoms 
can be explained by very high local concentrations of free 
histamine due to mast celt degranulation within the effector 
tissue and could therefore not be imitated by a systemic 
histamine injection. 
Other differences, however, in the incidence ratio of 
symptoms pointed to a considerable observer variation de- 
spite the effort made to diminish it (see Methods). "Metallic 
taste" was a frequent symptom in volunteers, but absent 
in patients. Retrolective assessment revealed that the ques- 
tion had been asked in patients as "irritation of taste". 
By this type of a question it was probably missed. Headache 
and "wet eyes" or tears were not asked about or looked 
for in patients at all in the operation theatre. Observer var- 
iation was by no means unique to the present study, but 
is well known to occur in general in clinical trials [8, 16, 
431. 
Since some higher plasma histamine levels were ob- 
served in patients than in volunteers more serious symp- 
toms, such as respiratory distress and bronchospasm, hypo- 
tension, vomitting and abdominal cramps and the necessity 
for emergency treatment were observed (Fig. 8). Thus these 
severe adverse responses to polygeline could be used to de- 
fine life-threatening histamine release response. In addition, 
a significant correlation was detected between the increase 
in pulse rate and the increase in plasma histamine levels 
(Fig. 9.). This correlation was slightly higher when absolute 
plasma histamine levels were encountered then when in- 
creases in plasma histamine concentrations were used. Thus 
tachycardia was not only the symptom with the highest 
incidence ratio, but also the parameter which best was cor- 
related with the plasma histamine levels. 
As in volunteers also in patients for diagnosing an aller- 
goid reaction only wheals and papules howed a high inci- 
dence ratio (Table 5). Pathological plasma histamine levels 
were measured only in two of the subjects. In all other 
cases the plasma histamine concentration remained within 
the normal range and did not differ significantly from the 
pre-infusion levels (Fig. 10). They were similar in patients 
with single or in those with many wheals, in patients with 
hives in one body region or in more than one. In particular, 
they were not significantly different from those in patients 
without any detectable r action. 
4. Decision-making Matrix for Diagnosing 
an Anaphylactoid Reaction to Polygeline 
by Pathological Plasma Histamine Levels 
The previous parts of Results were concentrated on the 
incidence ratios of pathological plasma histamine levels and 
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clinical signs in anaphylactoid reactions to histamine and 
polygeline. One of these indicants to be used for diagnosing 
an anaphylactoid reaction was analysed in a decision-mak- 
ing matrix for sensitivity, specificity and efficiency: the plas- 
ma histamine level (Fig. 11). 
As expected for this case with a predominant histamine 
releaser, the plasma histamine assay was a highly efficient 
test for diagnosing a systemic anaphylactoid reaction. 
Many other "potent"  diagnostic tools such as endoscopy 
and X-rays in peptic ulcer or measurement of plasma cate- 
cholamines in pheochromocytoma do not achieve more sat- 
isfactory results. 
Discussion 
The main aim of this study was to establish the diagnosis 
of  a histamine-release r sponse to an individual drug in 
an individual patient. One of the strategies for solving this 
problem is conducted in two steps: (1) Subjects with the 
disease and without the disease were selected by previously 
accepted criteria and indicants (case history data, clinical 
signs, laboratory tests etc) were collected by which these 
groups of subjects could be best discriminated. (2) Incidence 
ratios and conditional probabilities (e. g. sensitivity, speci- 
ficity) for these indicants were calculated [43] and those 
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a) Systemic react ion versus non-responders 
Test resu l t  SAR 
PHL > I ng/ml 26 
PHL ~ I ng/ml 4 
Totals 30 
Disease eta%us 
No SAR [ Totals 
I 
o 26 
38 42 
38 68 
26 . . . 38 Sens i%iv i ty~-~ = 87~; specz fzcz ty~ 100~ 
64 94~ e f f i c iency  ~ = 
b) Systemic react ion vezsus cutaneous reaction 
Test resu l t  SAR 
PHL > I ng/ml 26 
PPL ~ 1 ng/ml 4 
To%ale 30 
Disease s%atus 
No SAR Tota l s  
2 28 
94 98 
96 126 
Sensi%ivity 87~, speci f ic i%y 98%, e f f i c iency  95~ 
Fig, 11. Diagnostic decision-making matrix for plasma histamine 
level (test result) and systemic anaphylactoid reaction (disease sta- 
res). Two possibilities are shown for diagnosing a systemic anaphy- 
lactoid reaction (SAR): One in contrast to non-response and one 
in contrast o cutaneous response which is also a non-response 
as far as a systemic response isconcerned. PIlL = plasma histamine 
level. For further information see [43, 68] 
which are the most satisfactory predictors [15] were chosen 
for defining and classifying the disease [43, 71]. The defini- 
tion of the disease "histamine-release response" is based 
on symptoms and tests (accessible characteristics of the dis- 
ease according to Wulff [71], but it is also causally defined. 
This is one of the main advantages of this disease definition 
compared to the term "anaphylactoid reaction" which by 
far is more a syndrome [12] than a causally defined disease. 
Table 7. Indicants with highest incidence ratio in a systemic ana- 
phylactoid reaction (SAR) in conscious human subjects 
Group of Indicants for SAR Incidence 
subjects ratio [%] 
Vohmteers Tachycardia 97 
after i.v. Plasma histamine > 1 ng/ml 78 
histamine "Metallic" taste 75 
injection Flush 69 
Congestion of head 67 
"Wet eyes", tears 64 
Hypertension 58 
Headache 58 
Volunters Plasma histamine > 1 ng/ml 93 
with SAR Tachycardia 83 
following Wheals 58 
Haemaccel Sensation of heat 50 
Narrowness of throat 50 
Hypertension 50 
Headache 42 
"wet eyes", tears 42 
Patients Tachycardia 93 
with SAR Plasma histamine > 1 ng/ml 87 
following Erythema 70 
Haemaccel Wheals 60 
Cough 50 
Flush 43 
Stuffy nose 30 
Facial oedema 30 
Values taken from Tables 3, 4 and 6. Tachycardia=increase in 
heart and pulse rate/min resp. by more than 5 beats/min. Changes 
in blood pressure=increase or decrease by more than 10mmHg 
(systolic) 
The indicants with the highest incidence ratio in the 
3 conditions investigated were compiled in Table 7. Despite 
observer vatiation and different echniques for elevating the 
plasma histamine concentration there were marked similari- 
ties in the incidence ratio of several predictors: Tachycardia 
and plasma histamine levels > 1 ng/ml showed a very high 
incidence. Single wheals or a few of them and spots of 
erythema which have to be meticulously ooked for (Fig. 10) 
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occurred frequently following histamine release by polyge- 
line (see also [35, 55]) and "narrowness of throat" and 
"cough" were frequent symptoms in either the one or the 
other group of subjects which probably have the same path- 
ological substrate: histamine release and oedema in the la- 
ryngeal region. Other symptoms howed a variable inci- 
dence ratio in between the studies such as hypertension, 
"wet eyes" and tears, and headache, but this negative find- 
ing very probably can be changed by reducing observer 
variation [t 6]. Finally clinical symptoms originating from 
nasal mucosa, such as sneezing, stoffy nose, nasal catarrh 
etc. occur in about one-third of the cases and should prob- 
ably included in the definition of a systemic anaphylactoid 
reaction. 
Following the course of discussion it is now necessary 
to define an average histamine-release response in a more 
extended manner than in the section of Statistics and Defi- 
nitions. In part, the term "average" has a statistical mean- 
ing indicating the most frequent grade of severity of an 
anaphylactoid reaction observed in clinical conditions. In 
part, the term is a judgement since it does not include cuta- 
neous anaphylactoid reactions which by far are more fre- 
quent than systemic reactions. Thus an average histamine- 
release response is always a systemic histamine-release re-
sponse and as such a special case of an anaphylactoid reac- 
tion [12, 22, 39]. It is restricted to a syndrome in which 
histamine is the predominant mediator. For this reason in 
man the anaphylactoid reaction elicited by dextran and 
probably also by some other plasma substitutes [52] is not 
a histamine-release response, but may be an SRS-A or 
kinin-formation response. These examples hould demon- 
strate that controlled clinical trials in combination with 
methods of medical decision making may help to find the 
specific "quantitative spectrum" of signs, symptoms and 
biological reactions elicted by other mediators involved in 
anaphylactic and pseudo-allergic reactions. Serotonin, kin- 
ins, leukotrienes, prostaglandins all cause similar symptoms 
in man, but who ever knows whether these symptoms occur 
with the same incidence or have the same conditional prob- 
abilities as in a systemic histamine-release response? Thus 
medical-decision making may help to differentiate adverse 
drug reactions and constitute a new approach to their more 
successful prophylaxis and treatment. 
Using the indicants in Table 7 an average histamine- 
release response is a systemic anaphylactoid reaction which 
is characterized by clinical signs, such as tachycardia and 
mild hypertension, scattered hives such as spots of erythema 
and wheals, respiratory symptoms in the laryngeal and 
nasal region such as cough, narrowness in the throat, tuffy 
nose and sneezing and pathological plasma histamine levels 
(> 1 ng/ml). 
The classical symptoms of an "anaphylactic" reaction 
[3, 6t], such as hypotension, bronchospasm, and extended 
reactions in the skin with erythema or wheals covering large 
areas of the body are found only in 10% of systemic hista- 
mine-release r sponses. However, they are of great clinical 
importance for the life of patients and must not be underes- 
timated by the new definition of an average histamine-re- 
lease response. Also cutaneous reactions are not negligible 
events since they can indicate severe incidents in a second 
exposure to the drug [66] and may be associated with patho- 
logical processes such as platelet aggregation [69] or coagu- 
lation disturbances [6•] which hitherto have never been 
studied in volunteers or in patients. 
Table 8. Classification of histamine-release responses by verity 
Severity- Clinical symptoms Operational Plasma 
grade and criteria histamine 
groups of symptoms [ng/ml] 
I Erythema, urticaria Not considered _--< 1 ng/ml Cutaneous and/or dermal as threatening 
pruritus only No intensified 
observation, 
no treatment 
II Generalized skin Considered as > 1 ng/ml 
Systemic reactions plus threatening by 
discomfort, patient and 
tachycardia, doctor, 
arrhythmias, Intensified 
medium observation 
hypotension and/or treatment 
Respiratory 
distress 
III 
L~e- 
~reatening 
Severe hypotension Considered as 
(pulse and RR not life-threatening 
measurable) by doctor 
Ventricular Emergency treat- 
fibrillations, ment 
cardiac arrest 
Bronchospasm, 
respiratory arrest 
> 12 ng/ml 
For these reasons aclassification of histamine-release re- 
sponses by severity is necessary (Table 8). The limit for 
a plasma histamine level between a systemic and a life- 
threatening reaction was taken from the 3 severe incidents 
in the polygeline trial in patients. This classification, howev- 
er, is supported by plasma histamine values obtained in 
life-threatening reactions to anaesthetic agents [28]. Cuta- 
neous histamine-release responses i  general can be more 
accurately diagnosed by measuring histamine content in the 
blister fluid [21] if wheals occur in an individual patient, 
but this has not yet been worked out systematically. For 
polygeline, however, also cutaneous anaphylactoid reac- 
tions can be denoted as cutaneous histamine-release re- 
sponses since by H1- and H2-receptor antagonists it has 
been shown that histamine was the predominant mediator 
also in these kind of reactions [35, 55]. 
The definition of a histamine-release response by plasma 
histamine levels implicates a time problem. The velocity 
of plasma histamine increment shortly after drug applica- 
tion is explosive and the subsequent elimination is very fast, 
especially in cases with plasma histamine levels not higher 
than 5 ng/ml. Thus a histamine-release response can be de- 
fined quite easily [36, 39], but diagnosed reliably in an indi- 
vidual patient only if the blood samples were taken near 
or at the time of maximum response. It has been shown 
that the severity of the most striking symptoms, especially 
those in the circulatory system, run parallel to the kinetics 
of the plasma histamine levels [28, 34]. 
Adverse reactions which mimic the symptoms of ana- 
phylaxis were denoted as anaphylactoid or as pseudo-aller- 
gic reactions [12, 22, 39, 64]. Since histamine in experimen- 
tal animals [17, 47, 53, 70] and in human subjects under 
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certain circumstances elicits the 3 classical symptoms of 
anaphylaxis it was thought that histamine-release response 
should be diagnosed and defined by these symptoms or 
by some less severe variations of  these symptoms. However, 
this communication illustrates by one intensely studied 
example with one clinically used histamine releaser (experi- 
ments in animals and human subjects for more than /0 
years [29-32, 34, 39, 40, 44, 54] that the classical symptoms 
of  anaphylaxis are rare in histamine-release responses in 
general and only more common ("classical")  in grade I I I  
reactions. Increasing experience, however, in animals [6, 
25, 42, 49, 50, 60] and in man [61] is forming the suggestion 
that even this may not be true: Clinical pictures of  severe 
heart attack or arrhythmias may be caused by histamine- 
release responses which clearly have to be classified as gra- 
de I I I  reactions. 
Thus the highly controversial discussions about the inci- 
dences of adverse reactions to drugs which release histamine 
in man (for a survey see [2, 7, 11, 14, 39, 40, 52, 65, 67] 
can probably procede to a considerable agreement if tech- 
niques of  controlled trials [19] were combined with de- 
cision-making procedures to olve this problem. It is a clas- 
sical task of  medical-decision making to "use the diagnostic 
information to revise probabil it ies [68] or in other words 
to revise the figures for the incidences of adverse drug reac- 
tions. 
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Appendix 1. Recommendations for performing the interview and 
the clinical investigations: Ask the general questions at the begin- 
ning of every section. When clinical symptoms are detected please 
sign by a cross if they occur before infusion of drug injection. After 
drug administration note the mins of onset and disappearance. 
The authors thank very much A. Thornton and J. Watkins 
(University of Sheffield) for their help in the translation of this 
questionnaire. For continuous registration of heart rate and blood 
pressure a separate protocol was used. For additional informations 
about the symptoms of this questionnaire s e Lorenz et al. (1981 a). 
Present=from 9 months in the past until now (the moment of 
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interview), past = more than 9 months ago. Only in a few exceptions 
a more exact denotion of time was considered necessary (e. g. anaes- 
thetics, operations and trauma). In clinical findings sometimes 
more than one time had to be recorded for disappearance of a 
clinical symptom for reasons of accuracy. In this case the last 
number is the time finally accepted. "Coughing" has to be differen- 
tiated from "clearing one's throat" because otherwise the incidence 
of false-positive systemic responses is actually doubled or in the 
case of plasma substitutes tripled (short-term overload of the tung 
with fluid?). "Acceleration" or "slowing down" refers to the speed 
of infusion 
Questionnaire for diagnosis of a ,,hi, stamine-release response, 
Volunteer (patient) No 
Hospital number 1 
Name I ......... 
Se~ (m/f) 
Age [years] 
Height [cm] 
- page 1 - 
Hospital s taf f  (yes/no) ~ ;  
Occupation J J~-oL~J~ 4 ,~'~'~"~'~ 
Other personal data 
~(~-o~ ,h 26~ {~[  & ~/~ 
I tems 
Heart/Circulation 
High blood pressure 
E.C.G. changes 
Which ? I . . . . . . .  
Hear% failure 
Digitalis 
Angina 
Infarc%s 
Arrhythmi,as 
Renal disease 
Which ? 
Thyroid disease 
Which ? t 
Neurological disease 
Migrane 
Others ? J 
Liver disease 
Hepatitis 
Jaundice 
Porpbyrla 
Others ? I 
Lung disease 
Pneumonia 
Emphysema 
T.8. 
Others ? J 
Medical history (detai ls)  
Past 
+ - Items 
K 
y. 
:t 
~t 
Present 
+ - 
< 
x 
/ 
Past Present 
+ + 
Stomach/Intestinal disease )< 2 ~ 
Vomiting ~ P~ 
Diarrhoea / i~  
Ulcerative Colitis ~ 
Crohn's disease ~< 
Others ? 
Suppurative process ~ 
Abscess(e.g. appendix) ~ 
Furunculosis ~ 2< 
Others ? I 
Comment 
Metabolic disorders ~ 
Diabe±es ~ 
Obesity K 
Gout ~ )~ 
Others ? [ 
Infection ~ / 
Tonsilli±is X 
Rheumatic fever k k 
Others ? J 
i Au%olmmune disease ~ 
Rheumatoid ar%hri±is ~ A 
Other collagenoses ~ ~L 
Others ? l 
Joint disorders ~ [~ 
Which ? [ 
912 
Questionnaire continued 
Symptom 
I Anyth£ng peculiar? 
!Heta l l l c  taste 
Others ? I 
Sal lvary secretion 
Tight throat 
Eplgas%ric ful lness 
Nausea 
Heart burn 
Cramps, col lcs 
Straining 
Others ? I 
Sensation of  heat 
Red ears 
Erythema 
Flush 
Swollen ears 
BlepharoedemaZ ~:  ~ --  
Hives (wheols{~',~" ~c h 
Pruritus 
Con~unctivltls 
Qulncke's oedema 
Others ? I 
Cl in ica l  f£ndings 
Be- A f ter  
fore [mln - mln] Symptom 
- 3 ~  
- 3 - -#o  
- -  4 ~ 3 -  
d 
6 -- WZ- 
Tinnitus -- - -  
Congestion £n the head - - -  
Temporal pulsation - - 
Snezzlng 
Snuff ing 
Stuffed-up nose 
Nasal catarrh 
Narrowness in the chest 
Cough 
Respiratory distress 
Bronchospasm 
Others ? J 
Blurred sight 
Net eyes 
Others ? I 
Unrest ? I 
Swea±ing 
Tiredness 
Anxiety 
Palpi±ation 
Other vegetat ive 
symptoms ?1 
- page 3 - 
Be- Af ter  
fore [min - min. 
- A -  ~-#6 
,~  4~-m 
Time for bleeding [mini ,~. 40 
Time for infusion [mini 
Any slowing down? ~ 
Any acceleration? ~ 
Photo taken ~ 
Any comment ? 
Headache 
Nhere ? J 
Drowsiness 
Dizzlness 
Hang-over 
Others ? I 
Desire to pass water ~ -- 
Low back pain -- 
Feeling of  -body -- !A~ #o 
heaviness - feet  -- ~ ~ d u- 
Others ? I 
Questionnaire continued 
913 
Hypersensitivity history related to anaesthesia and surgery 
i~[ - i , | -+  - ; - 
Previous operations ~ Any drug incident 
Which and when ? ~r~ , ~"  - ~ Anaesthesia 
~y " H~, - . .~  Infusion substances 
Any hypersensitivity ~ x 
Asthma 7~ 
Hay fever ~ 
Eczema/dermatitis ~ 
Food )( X 
Which ? l 
Fruits V I 
Which ? I 
Animal hair 
Which ? J 
Cosmetic substances ~ )~ )< 
Shampoos ~ 
Soap X l~ 
Others ? J v i~-  ~. . . -  (u~'~ 
Drug hypersensitivity ~ 
Jodine ~ 
Adhesive plaster ~ 
Penicil l in ~ 
Aspirin ~ ;~ 
Phenacetin ~ 
Others ? [ 
i 
- page  2 - 
Y~ X 
y. x 
Contrast media ~ ;¢ 
Others ? J 
Medicines taken ~ )~ 
Analgesics,e.g. Aspirin ~ 
Sedatives, e.g. Valium )& 
Others ? I 
An:: : : : : : ics ~1 ~I  I : l  
Local,e.g. dental I ~1 
WhlcVWhen?l -~ / ~ 
Contrast media I XI I X 
Which/When? 
 ° osio° oubstances I I 1×1 
Whiah/When? J A/E (~/ ~ ' ~ A  ¢>~ 
Accidents 
Which/When? 
I 
Antibiotics I~  1 ] X 
Which ? I pe,.-,:~'~'% /<4~.,~c~c&~ 
Any comment ? I 
